Impact of ceftolozane/tazobactam concentrations in continuous infusion against extensively drug-resistant Pseudomonas aeruginosa isolates in a hollow-fiber infection model
Abstract Ceftolozane/tazobactam (C/T) has emerged as a potential agent for the treatment of extensively drug-resistant (XDR) Pseudomonas aeruginosa infections. As it is a time-dependent antimicrobial, prolonged infusion may help achieve pharmacokinetic/pharmacodynamic (PK/PD) targets. To compare alt...
Main Authors: | María M. Montero, Sandra Domene-Ochoa, Carla López-Causapé, Sonia Luque, Luisa Sorlí, Núria Campillo, Eduardo Padilla, Núria Prim, Lorena Ferrer-Alapont, Ariadna Angulo-Brunet, Santiago Grau, Antonio Oliver, Juan P. Horcajada |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2021-11-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-01784-4 |
Similar Items
-
Comparison of Ceftolozane/Tazobactam Infusion Regimens in a Hollow-Fiber Infection Model against Extensively Drug-Resistant Pseudomonas aeruginosa Isolates
by: María Milagro Montero, et al.
Published: (2022-06-01) -
Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates
by: María M. Montero, et al.
Published: (2021-09-01) -
Finding the Dose for Ceftolozane-Tazobactam in Critically Ill Children with and without Acute Kidney Injury
by: Laura Butragueño-Laiseca, et al.
Published: (2020-12-01) -
Suboptimal Concentrations of Ceftazidime/Avibactam (CAZ-AVI) May Select for CAZ-AVI Resistance in Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i>: In Vivo and In Vitro Evidence
by: Inmaculada Lopez-Montesinos, et al.
Published: (2022-10-01) -
Ceftolozane/Tazobactam Dosing Requirements Against Bacteremia
by: Jesus Ruiz, et al.
Published: (2020-01-01)